Press release
Granulocyte-Colony Stimulating Factor Category to Dominate the Oncology Biosimilars Market Through 2025
The demand for oncology biosimilar drugs has augmented in recent years. This is attributed to the rising prevalence of various types of cancers across the world. In addition, existing anti-cancer drugs in the pipeline are quite expensive, thus rendering them unaffordable to people in lower and middle income countries. As a consequence, the market for biosimilars has burgeoned.For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4800
However, the current COVID-19 pandemic is poised to stall growth trajectory of the market, owing to supply chain disruptions from leading biosimilar manufacturing hubs and shifting priorities of healthcare providers. These shifting priorities are delaying clinical trials for biosimilars, thus delaying their adoption. However, long-term prospects are highly optimistic, with the industry registering an aggrandizing CAGR of 29.4% by 2025-end.
Key Takeaways of Oncology Biosimilars Market Study:
• By drug class, the granulocyte-colony stimulating factor (G-CSF) category shall dominate the oncology biosimilars market, capturing more than 3/5th of the total market share. Rising adoption of chemotherapy is the key growth driver of the segment. However, monoclonal antibodies are set to grow the fastest, expanding 4.0x, attributed to modification of manufacturing facilities to develop complex and effective drugs.
For critical insights on this market, request for methodology here - https://www.factmr.com/connectus/sample?flag=RM&rep_id=4800
• By disease indication, the blood cancer and neutropenia segments are set to account for the majority of the market share, accounting for 22.3% and 54.7% respectively. Rising FDA approvals for biosimilar products manufactured by leading market players are attributed as key drivers behind the expansion. Examples of such drugs are filgrastim-sndz and filgrastim-aafi.
Global Oncology biosimilars Market Segmentation
Fact.MR has studied the global oncology biosimilars market with detailed segmentation on the basis of drug class, disease indication, distribution channel, and region.
Drug Class
• G-CSF
• Monoclonal Antibody
• Hematopoietic Agents
For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4800
Disease Indication
• Breast Cancer
• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Neutropenia
• Blood Cancer:
• Leukemia:
• Myeloid Leukemia
• Chronic Lymphocytic Leukemia (CLL)
• Non-Hodgkin Lymphoma
• Others
Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2019/09/11/1914156/0/en/Ill-Effects-of-Self-medication-Practices-to-Ramp-up-the-Adoption-of-Earwax-Removal-Aids-Fact-MR.html
Global Oncology Biosimilars Market: Competition Structure:
The global oncology biosimilars market consists of the following market players: Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh. This makes it a highly consolidated market. Collectively, these market players account for more than 70% of the market share. In order to increase their market footprints, these companies rely heavily on strengthening their product distribution networks through active collaborations.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Content Source: https://www.factmr.com/media-release/1569/global-oncology-biosimilars-market
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Granulocyte-Colony Stimulating Factor Category to Dominate the Oncology Biosimilars Market Through 2025 here
News-ID: 2329789 • Views: …
More Releases from Fact.MR
Trauma Devices Market is Estimated to Reach USD 29.1 Billion by 2035 | DePuy Syn …
Fact.MR today released its latest report on the Trauma Devices Market, providing comprehensive insights into the global market's robust growth driven by rising traumatic injuries, advancements in medical technologies, and increasing global awareness of trauma care. Valued at USD 12.9 billion in 2025, the market is projected to expand at a compound annual growth rate (CAGR) of 8.7%, reaching USD 29.1 billion by 2035.
For More Insights into the Market,…
Microbiome Therapeutics Market is Projected to Reach USD 3,121.8 Million by 2035 …
The global microbiome therapeutics market is valued at USD 823.5 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 14.2%, reaching USD 3,121.8 million by 2035. This robust expansion is driven by the increasing recognition of the human microbiome's role in managing chronic diseases, combined with rising investments in precision medicine and biotechnology innovation. As research uncovers the microbiome's influence on health conditions…
Insulin Patch Pumps Market is Anticipated to Reach USD 4.29 Billion by 2035
The global insulin patch pumps market is poised for substantial growth, with its valuation expected to rise from USD 1.42 billion in 2025 to USD 4.29 billion by 2035, reflecting a robust compound annual growth rate (CAGR) of 11.7%. This expansion is primarily driven by the escalating prevalence of diabetes worldwide and the increasing demand for convenient, discreet insulin delivery devices. As patients seek wearable insulin management systems that offer…
Wearable Payment Devices Market is Expanding USD 133.09 Billion by 2034 | Fact.M …
The global wearable payment devices market is valued at USD 33.47 billion in 2024 and is projected to expand to USD 133.09 billion by 2034, growing at a compound annual growth rate (CAGR) of 14.8%. This impressive growth is driven by the increasing adoption of contactless payment technologies, advancements in wearable devices, and rising consumer preference for convenient, secure transaction methods.
For More Insights into the Market, Request a Sample…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
